PrescriptionDrugs.org

Spironolactone

Key Takeaway

Spironolactone (brand name Aldactone) is a potassium-sparing diuretic and aldosterone antagonist. It is FDA-approved for heart failure, hypertension, edema from cirrhosis, nephrotic syndrome, and primary hyperaldosteronism. It is widely used off-label for hormonal acne and androgenetic alopecia in women.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.

Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.

Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.

See our Terms of Use and Editorial Policy.

How does Spironolactone work?

Spironolactone works by blocking the mineralocorticoid receptor (also called the aldosterone receptor) in the kidneys and other tissues throughout the body [1, 2]. Aldosterone is a hormone produced by the adrenal glands that normally signals the kidneys to retain sodium and water while excreting potassium. By blocking aldosterone's effects, spironolactone causes the kidneys to excrete sodium and water (producing a diuretic effect) while retaining potassium — this is why it is classified as a "potassium-sparing" diuretic [1, 3].

The clinical significance of this potassium-sparing property cannot be overstated. The landmark RALES trial (Randomized Aldactone Evaluation Study) demonstrated that adding low-dose spironolactone (25 mg/day) to standard heart failure therapy reduced mortality by 30% in patients with severe heart failure (NYHA class III-IV), establishing aldosterone antagonism as a cornerstone of modern heart failure management [3]. This benefit extends beyond simple diuresis — aldosterone contributes to cardiac fibrosis, endothelial dysfunction, and vascular inflammation, all of which spironolactone counteracts [3, 7].

Beyond its kidney and cardiovascular effects, spironolactone also blocks androgen receptors and weakly inhibits androgen synthesis (via 17-alpha-hydroxylase inhibition) [1, 4]. These anti-androgenic properties explain its widely used off-label applications for hormonal acne and hirsutism (excess hair growth) in women. By blocking the effects of testosterone and dihydrotestosterone at the skin level, spironolactone reduces sebum production and abnormal hair growth [4, 10].

Spironolactone is converted to several active metabolites in the body, including canrenone (half-life 16-22 hours) and 7-alpha-thiomethylspironolactone, which sustain the pharmacological effect well beyond the parent drug's short 1.4-hour half-life [1, 2].

What to expect when starting Spironolactone

Week 1: The diuretic effect begins within 2-3 days of starting spironolactone. You may notice increased urination as excess sodium and fluid are eliminated [1, 2]. Unlike loop diuretics (furosemide), the onset is gradual and the diuretic effect is moderate — spironolactone is not typically used for rapid fluid removal.

Weeks 2-4: Blood pressure-lowering effects develop gradually over this period [1, 3]. For heart failure patients, symptoms of congestion (shortness of breath, swelling) may begin to improve. Your physician will check potassium levels and kidney function within the first week and then at regular intervals — hyperkalemia (elevated potassium) is the most important safety concern with this medication [3, 12].

Months 1-3: For heart failure, the mortality benefit demonstrated in the RALES trial accrues over weeks to months of consistent therapy [3]. For hormonal acne or hirsutism, visible improvement typically requires 3-6 months of treatment, as the anti-androgenic effects take time to influence the hair and sebum production cycles [4, 10]. Patience is essential — dermatologic benefits are not immediate.

Hormonal side effects: You may notice breast tenderness or enlargement (gynecomastia in men, breast tenderness in women), which occurs in approximately 10% of patients and is related to the anti-androgenic and progestational effects [1, 3]. Women may experience menstrual irregularities, including spotting or amenorrhea [1, 4]. These effects are dose-dependent and may improve with dose reduction.

Ongoing monitoring: Long-term use requires periodic monitoring of potassium, creatinine, and blood pressure [1, 7, 12]. The risk of hyperkalemia is highest in patients with renal impairment, those taking ACE inhibitors or ARBs, and elderly patients.

What are the common side effects of Spironolactone?

Common

Common(10 effects)
  • Hyperkalemia (elevated potassium)5-10% (dose-dependent)
  • Gynecomastia (breast enlargement in males)5-10% (dose-dependent)
  • Breast tenderness5-15%
  • Menstrual irregularities (women)10-20%
  • Dizziness/lightheadedness5-10%
  • Nausea3-5%
  • Diarrhea2-5%
  • Fatigue/lethargy3-5%
  • Headache3-5%
  • Decreased libido2-5%

What are the serious side effects of Spironolactone?

Serious

Serious(4 effects)
  • Acute kidney injuryUncommon; more common in dehydration or with NSAIDs/ACE inhibitors
  • Hyponatremia (low sodium)2-5%
  • Metabolic acidosis (hyperchloremic)Uncommon
  • HepatotoxicityRare
Life-Threatening(2 effects)
  • Severe hyperkalemia (cardiac arrhythmias, cardiac arrest)1-3%; higher in renal impairment, elderly, or with ACE inhibitors/ARBs
  • Severe allergic reactionVery rare

What drugs interact with Spironolactone?

  • Major
    Lisinopril ACE inhibitors combined with spironolactone significantly increase hyperkalemia risk. This combination is used in heart failure under close monitoring but requires frequent potassium checks, especially in renal impairment. Start spironolactone at 12.5-25 mg with close monitoring.
  • Major
    Losartan ARBs plus spironolactone increase hyperkalemia risk. Triple RAAS blockade (ACE inhibitor + ARB + spironolactone) should be avoided. Monitor potassium closely if combined.
  • Moderate
    Hydrochlorothiazide Thiazide diuretics combined with spironolactone provide complementary diuretic effects but may cause excessive diuresis, hyponatremia, or electrolyte imbalances. The potassium-sparing effect of spironolactone partially offsets thiazide-induced potassium loss.
  • Major
    Meloxicam NSAIDs reduce the diuretic and antihypertensive effects of spironolactone and increase the risk of hyperkalemia and acute kidney injury. Avoid chronic NSAID use.
  • Major
    Potassium supplements Concurrent potassium supplementation with spironolactone dramatically increases hyperkalemia risk. Generally avoid potassium supplements unless potassium is documented as low despite spironolactone therapy.
  • Moderate
    Digoxin Spironolactone can increase digoxin levels by reducing renal clearance. Monitor digoxin levels and watch for toxicity signs. May need to reduce digoxin dose.
  • Moderate
    Lithium Diuretics including spironolactone may reduce lithium clearance and increase lithium levels. Monitor lithium levels closely.

View all drug interactions →

Can I eat certain foods or drink alcohol with Spironolactone?

Spironolactone should be taken with food, which increases absorption by approximately 100% and is generally recommended for optimal bioavailability [1, 2, 9]. Taking it with a meal also reduces the likelihood of gastrointestinal side effects.

Potassium-rich foods: While you do not need to eliminate potassium-rich foods from your diet, you should avoid dramatically increasing your intake of high-potassium items such as bananas, oranges, potatoes, tomatoes, avocados, and especially salt substitutes (which contain potassium chloride and can cause dangerous potassium elevation) [1, 7, 12]. Discuss your dietary potassium intake with your doctor, particularly if you are also taking an ACE inhibitor or ARB.

Alcohol: Alcohol may enhance the blood pressure-lowering effect of spironolactone, causing dizziness or lightheadedness, especially when standing up quickly (orthostatic hypotension) [1, 2]. Moderate consumption is generally acceptable for most patients. However, for patients taking spironolactone for liver cirrhosis with ascites, alcohol must be completely avoided as it directly worsens the underlying liver disease [11].

Natural licorice (glycyrrhizin): Avoid natural licorice root products, which contain glycyrrhizin — a compound that has aldosterone-like effects [1, 9]. Glycyrrhizin promotes sodium and water retention while increasing potassium excretion, directly counteracting spironolactone's therapeutic mechanism. Note that most American licorice candy is flavored with anise, not real licorice, and does not contain glycyrrhizin.

What is the typical dosage for Spironolactone?

Heart failure (NYHA class III-IV) [1, 3, 7]: - Starting: 25 mg once daily (12.5 mg if serum potassium >5.0 mEq/L or eGFR is borderline) - Target: 25-50 mg once daily - Check potassium at 1 week, then at 1 month, then every 3 months - Hold or reduce dose if potassium rises above 5.5 mEq/L

Hypertension [1, 2]: - Starting: 25-50 mg daily in 1-2 divided doses - Maximum: 100 mg/day (some resistant hypertension guidelines support up to 200 mg) - Particularly effective as add-on therapy for resistant hypertension

Edema from hepatic cirrhosis [1, 11]: - Starting: 100 mg daily (often combined with furosemide in a 100:40 mg ratio to maintain potassium balance) - Maximum: 400 mg/day - The spironolactone-to-furosemide ratio helps prevent both hypokalemia and hyperkalemia

Acne and hirsutism (off-label) [4, 10]: - Starting: 25-50 mg daily - Maintenance: 50-200 mg daily - Allow 3-6 months for full dermatologic effect - Lower doses (50-100 mg) are often sufficient for acne

Available strengths: 25 mg, 50 mg, 100 mg tablets [1, 2]. CaroSpir oral suspension (25 mg/5 mL) is available for patients unable to swallow tablets.

How much does Spironolactone cost?

Generic spironolactone is widely available and affordable, making cost rarely a barrier to treatment [1, 8].

Generic spironolactone tablets: Approximately $5-20 per month for most commonly prescribed doses (25-100 mg) [8]. Available on most $4 generic medication lists at major pharmacy chains. A 90-day supply is often $10-15.

Brand Aldactone: Largely discontinued in favor of generics. When available, it costs significantly more with no clinical advantage [1, 5].

CaroSpir (brand oral suspension): Substantially more expensive — approximately $200-400 per month. Use generic tablets when the patient can swallow them. For patients requiring a liquid formulation, compounding pharmacies can prepare spironolactone suspension at a fraction of the CaroSpir price.

Insurance coverage: Most insurance plans cover generic spironolactone at the lowest copay tier [8]. GoodRx coupons can further reduce out-of-pocket costs to as low as $4-8 for a 30-day supply.

Compared to eplerenone: Eplerenone (Inspra) is a more selective mineralocorticoid receptor antagonist with fewer anti-androgenic side effects, but it is significantly more expensive — $100-300+ per month even as a generic [8]. For most indications, spironolactone is the first-choice agent based on cost-effectiveness.

Is Spironolactone safe during pregnancy or breastfeeding?

Spironolactone is CONTRAINDICATED in pregnancy [1, 2, 6]. It crosses the placenta and its anti-androgenic effects pose a serious risk to male fetuses. Animal studies and case reports have documented feminization of male fetuses (ambiguous genitalia) when exposed to spironolactone or similar anti-androgens during critical periods of sexual differentiation [1, 6].

Women of childbearing potential should use effective contraception while taking spironolactone [1, 4]. For women using spironolactone for acne or hirsutism, many dermatologists recommend concurrent oral contraceptive use, which provides both contraception and complementary anti-androgenic effects [4, 10]. Pregnancy testing may be recommended before initiating therapy.

If pregnancy occurs while taking spironolactone, the medication should be discontinued immediately and the patient should consult their obstetrician. The risk of fetal harm is greatest during the first trimester when genital differentiation occurs, but exposure at any gestational age is concerning [1, 6].

Breastfeeding: Canrenone, the primary active metabolite of spironolactone, is excreted in breast milk [1, 2]. The WHO considers spironolactone compatible with breastfeeding at doses up to 200 mg/day, based on estimated infant exposure levels. However, some clinical references recommend caution, particularly at higher doses. Monitor the infant for any adverse effects including poor feeding, lethargy, or GI disturbance [9]. If an aldosterone antagonist is needed during lactation, discuss the risks and benefits with both the prescriber and pediatrician.

Is there a generic version of Spironolactone?

Generic spironolactone has been available for decades and is the universal standard of care [1, 2, 5]. All generic spironolactone tablets are FDA-rated AB (therapeutically equivalent) to brand Aldactone, meaning they have demonstrated identical bioavailability in controlled pharmacokinetic studies [5].

There is no clinical reason to use brand-name Aldactone over generic spironolactone [1, 5, 8]. The active ingredient, dosing, and therapeutic outcomes are identical. Generic spironolactone is available from multiple manufacturers in 25 mg, 50 mg, and 100 mg tablet strengths.

CaroSpir is a branded oral suspension (25 mg/5 mL) designed for patients who cannot swallow tablets — including elderly patients with dysphagia and pediatric patients [2]. It is significantly more expensive than generic tablets. For patients needing a liquid formulation, a compounding pharmacy can prepare spironolactone oral suspension from crushed tablets at substantially lower cost.

Eplerenone (Inspra) is an alternative MR antagonist with greater selectivity for the mineralocorticoid receptor and fewer anti-androgenic side effects (less gynecomastia, no menstrual irregularity) [7]. However, eplerenone is considerably more expensive and is typically reserved for patients who cannot tolerate spironolactone's hormonal side effects.

For Caregivers

Caregivers should be aware of spironolactone's unique monitoring requirements, as potassium monitoring is critical for patient safety [1, 3, 7, 12].

Hyperkalemia (high potassium) is the most dangerous potential side effect and can cause life-threatening heart rhythm problems [3, 12]. Ensure blood tests for potassium and kidney function are completed on schedule — typically at 1 week after starting, then monthly for the first 3 months, then every 3 months thereafter [1, 7]. After the RALES trial results were published, a significant increase in hyperkalemia-related hospitalizations was documented, underscoring the importance of proper monitoring [12].

Signs of hyperkalemia to watch for: Muscle weakness, tingling or numbness in extremities, slow or irregular heartbeat, nausea, and fatigue [1, 7]. If any of these symptoms develop, seek immediate medical attention and have potassium levels checked urgently.

Diet management: Help the patient avoid excessive potassium intake — large quantities of bananas, oranges, potatoes, tomato products, and especially salt substitutes (which contain potassium chloride) [1, 12]. Maintain a consistent dietary pattern rather than making dramatic changes.

Hormonal effects: Male patients may develop breast tenderness or enlargement (gynecomastia), which occurs in approximately 10% of patients at standard doses [1, 3]. Female patients may experience menstrual irregularities, breast tenderness, or changes in libido [1, 4]. These are expected pharmacological effects, not emergencies, but should be discussed with the prescriber if bothersome — eplerenone may be considered as an alternative with fewer hormonal effects [7].

Frequently asked questions about Spironolactone

References

  1. [Regulatory] Aldactone (spironolactone) tablets prescribing information. Pfizer. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/012151s079lbl.pdf Accessed 2025-01-15.
  2. [Regulatory] DailyMed — Spironolactone tablet label. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be8bfb58-7058-4a63-ad48-8a3250daa3ce Accessed 2025-01-15.
  3. [Clinical] Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES). N Engl J Med. 1999;341(10):709-717. https://pubmed.ncbi.nlm.nih.gov/10471456/ Accessed 2025-01-15.
  4. [Clinical] Layton AM, Eady EA, Whitehouse H, et al. Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review. Am J Clin Dermatol. 2017;18(2):169-191. https://pubmed.ncbi.nlm.nih.gov/28155090/ Accessed 2025-01-15.
  5. [Regulatory] Drugs@FDA: FDA-Approved Drugs — Aldactone NDA 012151. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=012151 Accessed 2025-01-15.
  6. [Clinical] Runcie CJ, Purdie DW. Spironolactone, pregnancy, and feminization of the male fetus. Lancet. 1994;344(8936):1578. https://pubmed.ncbi.nlm.nih.gov/7983974/ Accessed 2025-01-15.
  7. [Clinical] Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of Heart Failure Management Guidelines. J Am Coll Cardiol. 2017;70(6):776-803. https://pubmed.ncbi.nlm.nih.gov/28461007/ Accessed 2025-01-15.
  8. [Observational] GoodRx. Spironolactone Prices, Coupons & Savings Tips. https://www.goodrx.com/spironolactone Accessed 2025-01-15.
  9. [Regulatory] UpToDate. Spironolactone: Drug information. Wolters Kluwer. https://www.uptodate.com/contents/spironolactone-drug-information Accessed 2025-01-15.
  10. [Clinical] Kim GK, Del Rosso JQ. Oral spironolactone in post-teenage female patients with acne vulgaris. J Clin Aesthet Dermatol. 2012;5(3):37-50. https://pubmed.ncbi.nlm.nih.gov/22468178/ Accessed 2025-01-15.
  11. [Clinical] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. https://pubmed.ncbi.nlm.nih.gov/29653741/ Accessed 2025-01-15.
  12. [Clinical] Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351(6):543-551. https://pubmed.ncbi.nlm.nih.gov/15295047/ Accessed 2025-01-15.

Written and fact-checked by PrescriptionDrugs.org Editorial Team

Last updated: